Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans

International Journal of Obesity

Volumn 34, Issue 5, 2010, Pages 846-851

  Felder, T K ^a   Hahne, P ^a   Soyal, S M ^a   Miller, K ^b   Hoffinger H ^b   Oberkofler, H ^a   Krempler, F ^b   Patsch, W ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Krankenhaus Hallein   (Austria)

Author keywords

ADIPOR1; ADIPOR2; FOXO1; Insulin resistance; Liver

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; MESSENGER RNA; TRANSCRIPTION FACTOR FKHR; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPOR1 PROTEIN, HUMAN; ADIPOR2 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL STRAIN HEPG2; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK FACTOR; RNA TRANSCRIPTION; UPREGULATION; BLOOD; BODY MASS; GENE EXPRESSION; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

ADIPONECTIN; ADULT; BODY MASS INDEX; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; RECEPTORS, ADIPONECTIN; RISK FACTORS; RNA, MESSENGER;

ANIMALIA;

EID: 77952288558     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.7     Document Type: Article

References (49)

1. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-1100.
2. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
3. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008; 24: 320-327. (Pubitemid 351535891)
4. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271-278.
5. Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006; 17: 162-169.
6. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-3194.
7. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
8. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-853.
9. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008; 8: 923-934.
10. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168: 1617-1624.
11. Aguilar-Salinas CA, Garcia EG, Robles L, Riano D, Ruiz-Gomez DG, Garcia-Ulloa AC et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008; 93: 4075-4079.
12. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
13. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
14. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363.
15. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085.
16. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
17. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339.
18. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
19. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
20. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817-30822.
21. Pontiroli AE, Pizzocri P, Giacomelli M, Marchi M, Vedani P, Cucchi E et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002; 12: 648-651.
22. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004; 55: 729-732.
23. Oberkofler H, Linnemayr V, Weitgasser R, Klein K, Xie M, Iglseder B et al. Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 2004; 53: 1385-1393.
24. Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001; 28: 178-183.
25. Hahne P, Krempler F, Schaap FG, Soyal SM, Hoffinger H, Miller K et al. Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans. J Intern Med 2008; 264: 452-462.
26. Oberkofler H, Esterbauer H, Linnemayr V, Strosberg AD, Krempler F, Patsch W. Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 2002; 277: 16750-16757.
27. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F et al. Adiponectin and its receptors in non-alcoholic steatohepa-titis. Gut 2005; 54: 117-121. (Pubitemid 40007229)
28. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005; 39: 237-242.
29. Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A et al. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 2009; 19: 467-474.
30. Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzani AL, Zappa M et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355-1362.
31. Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS. Diagnostic value of ultrasonographic examination for nonalcoholic steato-hepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 2007; 17: 45-56.
32. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555.
33. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
34. Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 2009; 39: 724-738.
35. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-1183.
36. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishi-ma M et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-1938.
37. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005; 48: 2282-2291. (Pubitemid 41618919)
38. Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen KH, Westerbacka J et al. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol 2009; 160: 593-602.
39. Zhang P, Wang Y, Fan Y, Tang Z, Wang N. Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29: 67-74.
40. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) 2006; 14: 28-35.
41. Bluher M, Williams CJ, Kloting N, Hsi A, Ruschke K, Oberbach A et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007; 30: 3110-3115.
42. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 2004; 47: 816-820.
43. Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 2004; 47: 917-925.
44. Bluher M, Bullen Jr JW, Lee JH, Kralisch S, Fasshauer M, Kloting N et al. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006; 91: 2310-2316.
45. Staiger H, Kaltenbach S, Staiger K, Stefan N, Fritsche A, Guirguis A et al. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 2004; 53: 2195-2201.
46. Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999; 274: 16741-16746.
47. Nakae J, Park BC, Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 1999; 274: 15982-15985.
48. Sun X, He J, Mao C, Han R, Wang Z, Liu Y et al. Negative regulation of adiponectin receptor 1 promoter by insulin via a repressive nuclear inhibitory protein element. FEBS Lett 2008; 582: 3401-3407.
49. Sun X, Han R, Wang Z, Chen Y. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Diabetologia 2006; 49: 1303-1310.